64
Participants
Start Date
March 25, 2022
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2029
Durvalumab
1500 mg IV infusion every 4 weeks for up to 7 doses
S-488210/S-488211
S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
RECRUITING
Guy's and St Thomas' NHS Foundation Trust, London
RECRUITING
The Royal Marsden NHS Foundation Trust, London
RECRUITING
University College London Hospital NHS Foundation Trust, London
RECRUITING
The Christie NHS Foundation Trust, Manchester
RECRUITING
University Hospital Southampton NHS Foundation Trust, Southampton
Collaborators (2)
AstraZeneca
INDUSTRY
Shionogi
INDUSTRY
University College, London
OTHER